Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Gro ...

药物研发进展 - 公司已向美国FDA提交了crofelemer用于治疗微绒毛包涵体病（MVID）儿科患者的修正试验方案，以支持其可能的加速批准路径 [1] - 该药物有潜力延长MVID患者的生命，这些婴幼儿患者面临致命的疾病自然史 [1] - 在MVID患者中，crofelemer可实现高达37%的肠外营养支持减少，这一突破意义重大 [1] 疾病与市场背景 - 微绒毛包涵体病（MVID）是一种超罕见遗传病，患者天生无法吸收基本生命营养素 [1] - 目前全球任何地区均无针对MVID的获批治疗方法 [1] - MVID患者需要终身接受肠外营养支持，但这与毒性和合并症相关 [1]